hematologic

Related by string. Hematologic * * hematologic toxicity correlated . hematologic malignancies . hematologic cancers . hematologic toxicity . Hematologic Malignancies . hematologic toxicities . common hematologic malignancy . hematologic malignancy . hematologic adverse reactions . hematologic diseases . hematologic adverse . hematologic disorders . hematologic tumors *

Related by context. All words. (Click for frequent words.) 73 hematological 67 complete remissions 65 haematologic 65 cytogenetic response 65 cytogenetic responses 64 myelosuppression 64 haematological 64 evaluable patients 64 lymphopenia 63 partial remissions 62 heavily pretreated patients 62 MCyR 62 hematologic adverse 62 evaluable 61 patients evaluable 61 azacitidine 61 essential thrombocythemia 61 hematologic toxicity 61 cytopenias 61 peripheral sensory neuropathy 61 hematologic malignancies 60 adverse cytogenetics 60 histologies 60 sarcomatoid 60 myeloproliferative diseases 60 splenectomized patients 60 laboratory abnormalities 60 lymphocytosis 60 remission CR 60 RECIST criteria 60 tumor regressions 60 neutropenia dehydration dyspnea 59 dose limiting toxicities 59 heavily pretreated 59 tumor regression 59 anti leukemic 59 epithelial tumors 59 myelofibrosis 59 ara C 59 complete cytogenetic 59 leukemia AML 59 relapsed refractory 58 xenograft models 58 febrile neutropenia 58 hematological malignancies 58 chlorambucil 58 malignancies 58 anemia neutropenia 58 CR CRu 58 RECIST Response Evaluation Criteria 58 Hematologic 58 tumor malignancies 58 Solid Tumors criteria 58 chronic GVHD 58 Xanafide 58 galiximab 58 dose cohorts 58 neutropenia thrombocytopenia 58 cutaneous T cell 58 hematologic cancers 58 papillary renal cell carcinoma 58 imatinib resistant 57 chemotherapy regimens 57 pheochromocytoma 57 hA# 57 antitumor activity 57 HSCT 57 HBeAg positive patients 57 metastatic GIST 57 eculizumab 57 CCyR 57 erythropoietic 57 demonstrated antitumor activity 57 CR nPR 57 DLTs 57 Flu Cy 57 MGd 57 pathologic 57 myeloproliferative neoplasms 57 HBeAg negative patients 57 refractory AML 57 plasma uric acid 57 EGFRIs 57 limiting toxicity 57 hypercalcemia 57 cell lymphoma CTCL 57 follicular lymphomas 57 Ph + ALL 57 tumor xenograft models 57 decitabine 57 relapsed MM 57 achieved ACR# 57 lymphoma subtypes 56 relapsed refractory multiple myeloma 56 toxicities 56 bone marrow suppression 56 molecular remissions 56 Fludara 56 dasatinib 56 neoplastic 56 nodular partial response 56 Gleevec resistant 56 Toxicities 56 mRCC 56 Response Evaluation Criteria 56 interferon alfa 2b 56 lymphomas 56 refractory NSCLC 56 Myelofibrosis 56 RBC transfusion 56 response pCR 56 myelofibrosis polycythemia vera 56 GvHD 56 secondary efficacy endpoints 56 tumor shrinkage 56 histologic 56 platinum refractory 56 indolent NHL 56 Primary endpoints 56 deletion 5q 56 squamous 56 lymphoma CTCL 56 pomalidomide 56 pancytopenia 56 carcinoid 56 CRp 56 Telintra 56 myelodysplastic syndrome MDS 56 cutaneous T 56 splenectomized 56 acute GvHD 56 tumoral 56 receptor tyrosine kinase inhibitor 56 leukemia APL 56 cell lymphomas 56 chronic myeloid leukemia CML 56 ALT flares 56 histological subtypes 56 chronic lymphocytic leukemia CLL 56 recurrent glioblastoma multiforme 56 daunorubicin 56 tumor lysis syndrome 56 imatinib therapy 56 lesional 56 chemoradiation 55 hematological toxicity 55 rituximab 55 malignant fibrous histiocytoma 55 hematologic disorders 55 DOXIL 55 #mg/m# [001] 55 dasatinib Sprycel ® 55 leukemia ALL 55 follicular NHL 55 glioblastoma multiforme GBM 55 follicular lymphoma 55 CHOP chemotherapy 55 TREANDA 55 myeloid 55 immunomodulation 55 thalidomide Thalomid 55 pediatric acute lymphoblastic 55 oblimersen 55 non metastatic osteosarcoma 55 4mg/kg 55 severe hypersensitivity reactions 55 CTAP# Capsules 55 T#I mutation 55 ribavirin RBV 55 vWD 55 ovarian carcinoma 55 pancreatic adenocarcinoma 55 FOLPI 55 histologic subtype 55 mcg albinterferon alfa 2b 55 mg kg dose 55 clinicopathological 55 differentiated thyroid 55 plus methotrexate 55 nephrotoxicity 55 Thrombocytopenia 55 haematological malignancies 55 unfavorable cytogenetics 55 neoplasm 55 neuroendocrine cancers 55 Ph + 55 leukemic 55 ponatinib 55 refractory acute myeloid 55 CVP chemotherapy 55 MYLOTARG 55 papillary 55 elevated ALT 55 myeloproliferative disorders 55 non hematological toxicities 55 osteosarcomas 55 Sezary syndrome 55 ACTEMRA TM 55 mitomycin 55 tanespimycin 55 cutaneous squamous cell carcinoma 55 multiple myeloma MM 55 neurological manifestations 55 PNH patients 55 unresectable 55 bendamustine 55 hepatic encephalopathy HE 55 immune mediated 55 ACZ# 55 lenalidomide Revlimid R 55 astrocytomas 55 idiopathic thrombocytopenic purpura 54 mg/m2 dose 54 epirubicin 54 FluCAM 54 PXD# 54 imatinib 54 non Hodgkin lymphomas 54 systemic ALCL 54 HGS ETR1 54 atypical hemolytic uremic syndrome 54 Dacogen injection 54 hypereosinophilic syndrome 54 vinorelbine 54 antitumour activity 54 tumor histology 54 CYT# potent vascular disrupting 54 Omacetaxine 54 solid tumors 54 KRAS status 54 atypical Hemolytic Uremic Syndrome 54 hematopoietic 54 neurotoxicity 54 Doxil ® 54 acute myeloid 54 SJIA 54 nilotinib 54 monotherapy 54 mg BID 54 CANCIDAS 54 myelodysplastic syndromes MDS 54 evaluable subjects 54 rFVIIa 54 generalized seizures 54 dosage regimens 54 doxorubicin cyclophosphamide 54 Hematologic toxicity 54 peripheral blood mononuclear 54 FLT3 54 Cutaneous T 54 EXJADE 54 alanine aminotransferase ALT 54 Secondary endpoints include 54 EGFR HER2 54 intravascular hemolysis 54 metastatic malignant 54 mycosis fungoides 54 TNF antagonist 54 cytoreduction 54 FOLFOX 54 metastatic renal cell carcinoma 54 ACTEMRA 54 remyelination 54 rituximab refractory 54 gemcitabine Gemzar ® 54 follicular lymphoma FL 54 posaconazole 54 standard chemotherapy regimens 54 familial amyloidotic polyneuropathy FAP 54 TORISEL 54 receiving highly emetogenic 54 tolvaptan 54 panobinostat 54 bortezomib 54 relapsing remitting 54 alfa 2a 54 INCB# [003] 54 intracranial hemorrhage ICH 54 IV NSCLC 54 hepatic failure 54 metastatic malignant melanoma 54 Diffuse Large B 54 transaminase elevations 54 mycophenolate mofetil 54 cisplatin gemcitabine 54 CLL SLL 54 discontinuations due 54 prognostic factors 54 lymphoid malignancies 54 serous ovarian cancer 54 sarcomas 54 stage IIIb 54 leukemia CLL 54 K ras mutations 54 lupus nephritis 54 mTOR inhibitors 54 clinically meaningful 54 prokinetic agent 54 acute myeloid leukemia AML 54 histological subtype 54 mg/m2/day 54 therapeutic regimens 54 Acute myelogenous leukemia 54 cisplatin chemotherapy 54 composite endpoint 54 cancer mCRC 54 refractory CTCL 54 renal toxicity 54 Amrubicin 54 NSCLC 54 metastatic RCC 54 melphalan prednisone 54 Hurthle cell 54 carcinoid tumors 54 DMARD 54 relapsers 54 erythropoiesis 54 INCB# [001] 54 achieved PASI 54 teriflunomide 54 SSc 54 sensory neuropathy 54 antiangiogenic therapy 54 lenalidomide dexamethasone 54 elacytarabine 53 HCV genotypes 53 null responders 53 leukemia CML 53 EGFR inhibitors 53 huN# DM1 53 haematopoietic 53 Ph + CML 53 carboplatin paclitaxel 53 JAK2 V#F 53 alpha interferons 53 virological failure 53 pegylated liposomal doxorubicin 53 liver histology 53 alkylating agent 53 kinase inhibition 53 Secondary endpoints 53 tumor necrosis 53 gastric carcinoma 53 radiolabeled TM# 53 MDS AML 53 recurrent GBM 53 prior chemotherapy regimens 53 histologically 53 CIMZIA TM 53 sJIA 53 MALT lymphoma 53 cytopenia 53 seropositive patients 53 hepatic cirrhosis 53 myeloproliferative disorder 53 TELINTRA 53 thyroid carcinoma 53 azacytidine 53 mitoxantrone 53 systemic lupus erythematosus SLE 53 Solid Tumors 53 ependymomas 53 IL 1ß 53 plus dexamethasone 53 malignant lymphocytes 53 B CLL 53 gemcitabine carboplatin 53 HER2 positive metastatic breast 53 KRAS wild 53 erlotinib Tarceva ® 53 Pharmacokinetics PK 53 Sudhir Agrawal D.Phil 53 brain metastases 53 demonstrated clinically meaningful 53 OncoVEX GM CSF 53 VIDAZA 53 etoposide 53 hematologic malignancy 53 Epratuzumab 53 pharmacodynamic 53 evaluating REVLIMID 53 hematological cancers 53 ON #.Na 53 refractory cutaneous T 53 FOLFIRI 53 metastatic lesions 53 neurotrophic 53 hepatorenal syndrome 53 pCR 53 Psoriasis Area 53 visceral metastases 53 cytogenetic abnormalities 53 Vojo Vukovic MD Ph.D. 53 placebo controlled clinical trials 53 cilengitide 53 docetaxel chemotherapy 53 relapsed multiple myeloma 53 relapsed AML 53 remission induction 53 Darinaparsin 53 glomerular filtration 53 TEAEs 53 acute coronary syndromes ACS 53 8mg/kg 53 headache nasopharyngitis 53 systemic anaplastic large 53 plus gemcitabine 53 TTF Therapy 53 metastatic CRC 53 dexamethasone Decadron 53 ascending dose 53 Acute lymphoblastic leukemia 53 idiopathic thrombocytopenic purpura ITP 53 methotrexate monotherapy 53 superficial bladder cancer 53 adriamycin 53 fluorouracil 53 histologically confirmed 53 ansamycin 53 generalized tonic clonic seizures 53 LHRH analogues 53 canakinumab 53 refractory multiple myeloma 53 low dose cytarabine 53 vWF 53 hematopoietic cancers 53 TRAIL R1 53 soft tissue sarcomas 53 milatuzumab 53 Allovectin 7 ® 53 Cloretazine 53 Seliciclib 53 certolizumab 53 affective psychosis 53 FOLFOX4 53 Follicular Lymphoma 53 leukaemias 53 ganetespib 53 Myelodysplastic syndromes MDS 53 neurologic progression 53 chronic eosinophilic leukemia 53 stage IIIB 53 locoregional 53 ascending doses 53 relapsed MCL 53 Chronic lymphocytic leukemia CLL 53 immunologic 53 depsipeptide 53 novel VDA molecule 53 mg/m2 53 polycythemia vera PV 53 HBeAg positive 53 samalizumab 53 intermittent dosing 53 TACE 53 lymphoid blast 53 posttransplant 53 CYT# 53 IMC A# 53 CD# antibody [001] 53 imatinib Gleevec ® 53 refractory chronic lymphocytic 52 Fludarabine 52 CMV disease 52 basal cell carcinoma BCC 52 chemoradiotherapy 52 Bezielle 52 hepatocellular carcinomas 52 glufosfamide 52 dosing cohorts 52 corticosteroid therapy 52 interferon alfa 52 ixabepilone 52 APTIVUS r 52 ADHF 52 thymoma 52 immune thrombocytopenic purpura ITP 52 essential thrombocythemia ET 52 complete cytogenetic response 52 HGS ETR2 52 lymphoid 52 PCNSL 52 ANCA associated 52 glioblastoma 52 FOLFIRINOX 52 MabCampath 52 alkylating agents 52 myeloproliferative 52 VGPR 52 neurogenic 52 hepatitis C genotype 52 OHR/AVR# 52 DLBCL 52 kidney urologic 52 recurrent glioblastoma 52 surrogate endpoint 52 BCG refractory 52 pharmacodynamic PD 52 HES CEL 52 mycophenolate mofetil MMF 52 INCB# [002] 52 chemotherapeutic regimens 52 Taxotere ® 52 hematological diseases 52 hypoperfusion 52 timepoints 52 dacarbazine 52 ELACYT 52 gastrointestinal stromal tumors GIST 52 hepatocellular 52 clinically meaningful differences 52 apremilast 52 cytogenic 52 RBC transfusions 52 malignant neoplasms 52 anti angiogenic agents 52 adalimumab 52 prospectively defined 52 estramustine 52 dosing cohort 52 allogeneic stem cell 52 ribavirin therapy 52 gastrointestinal perforation 52 paragangliomas 52 hepatic metastases 52 metastatic kidney 52 hypomethylating agents 52 IFN α 52 Apoptone 52 diabetic nephropathy 52 KRAS mutations occur 52 sodium thiosulfate STS 52 favorable pharmacokinetic profile 52 #mg BID [001] 52 pulmonary toxicity 52 elotuzumab 52 rituximab Rituxan 52 acute myelogenous leukemia AML 52 hematological parameters 52 clinically meaningful improvements 52 Lymphomas 52 squamous cell carcinoma SCC 52 microtubule targeting 52 Hsp# inhibition 52 Etanercept 52 antibody MAb 52 hematopoietic malignancies 52 chronic myeloid 52 riociguat 52 eosinophilic asthma 52 refractory Hodgkin lymphoma 52 romiplostim 52 invasive aspergillosis 52 crizotinib PF # 52 Dose limiting toxicities 52 SCCHN 52 olanzapine LAI 52 aHUS 52 HBeAg negative 52 EDSS scores 52 disease modifying antirheumatic 52 #mg/m# [002] 52 linear pharmacokinetics 52 imetelstat 52 VAPRISOL 52 hematopoietic cell 52 mutated KRAS 52 antimetabolite 52 grade cervical intraepithelial 52 carcinomas 52 CIMZIA ™ 52 octreotide LAR 52 anthracyclines taxanes 52 distant metastasis 52 imatinib Gleevec 52 desvenlafaxine succinate 52 myelodysplastic syndromes 52 Waldenstrom macroglobulinemia 52 thrombocytosis 52 HER2 overexpression 52 FOLFOX6 52 macroalbuminuria 52 viral kinetics 52 neoplasms 52 trastuzumab Herceptin ® 52 serum antibody 52 tyrosine kinase inhibitors 52 investigational therapies 52 response CCyR 52 zalutumumab 52 comparator arm 52 Decitabine 52 endothelin receptor antagonists 52 FUSILEV enhances 52 macroglobulinemia 52 postoperative chemotherapy 52 virologic responses 52 T1DM 52 refractory gout 52 Vidofludimus 52 paclitaxel cisplatin 52 thromboembolic events 52 immunomodulatory therapy 52 fibrotic disease 52 lymphoproliferative disorders 52 potentially hepatotoxic 52 cardiac dysfunction 52 #ME# 52 gastric adenocarcinoma 52 Neulasta ® 52 Enzastaurin 52 CsA 52 investigational compounds 52 clinically relevant 52 endothelial activation 52 mCRC patients 52 Carfilzomib 52 hemolytic 52 idarubicin 52 plus ribavirin 52 RoACTEMRA 52 metastatic melanoma 52 Chronic Lymphocytic Leukemia CLL 52 Perifosine 52 trabectedin 52 biologic therapy 52 corticosteroids immunoglobulins 52 renal tumors 52 HBeAg seroconversion 52 anterior uveitis 52 AP# [003] 52 invasive bladder 52 sUA 52 velafermin 52 paclitaxel Taxol ® 52 NAGS deficiency 52 dacarbazine DTIC 52 Vidaza azacitidine 52 tolerability 52 ELOXATIN 52 oral prodrug 52 cytotoxic chemotherapy 52 serologically active systemic lupus 51 allogeneic SCT 51 PRECiSE 51 investigational monoclonal antibody 51 fallopian tube cancers 51 icatibant 51 SPRYCEL ® 51 intravesical therapy 51 MELAS 51 fluoropyrimidine 51 unknown etiology 51 efalizumab 51 T#I mutant 51 topotecan 51 relapsed SCLC 51 pegylated interferon alfa 51 torsade de pointes 51 fludarabine cyclophosphamide 51 tumor progression 51 clinico pathological 51 grade glioma 51 CIMZIA TM certolizumab pegol 51 T#I [002] 51 Pegasys ® 51 Kit CD# positive 51 juvenile idiopathic arthritis 51 severe oral mucositis 51 Cell Lymphoma 51 recovery CRp 51 PASI scores 51 xenograft tumors 51 calcineurin inhibitors 51 uric acid lowering 51 pimecrolimus cream 51 GOUT 51 carcinoids 51 cutaneous 51 hyperoxaluria 51 allogeneic transplant 51 ISTODAX 51 Soliris therapy 51 severe neutropenia 51 hepatic encephalopathy 51 NLX P# 51 sarcoma melanoma 51 anthracycline 51 skeletal metastases 51 leukemias 51 recurrent genital herpes 51 mucinous 51 achieved sustained virological 51 previously untreated follicular 51 Sjögren syndrome 51 juvenile idiopathic arthritis JIA 51 lymphocytic 51 astrocytoma 51 progression TTP 51 infliximab 51 Ribavirin causes 51 neuroendocrine tumors 51 PAOD 51 folinic acid 51 Azedra 51 systemic autoimmune 51 5-fluorouracil/leucovorin 51 Chronic myeloid leukemia CML 51 vandetanib 51 colorectal liver metastases 51 GISTs 51 Glucocorticoids 51 radiochemotherapy 51 sustained virological response 51 HRPC 51 castrate resistant 51 PREZISTA r 51 gemcitabine Gemzar 51 small lymphocytic lymphoma 51 pancreatic carcinoma 51 renal cell carcinoma 51 tipranavir ritonavir 51 hypopituitarism 51 locoregional recurrence 51 myeloablative 51 Hepatocellular Carcinoma HCC 51 demyelinating 51 IRX 2 51 Neutropenia 51 intravesical 51 proteasome inhibitor 51 SUTENT 51 cabazitaxel 51 refractory CLL 51 MabThera Rituxan 51 null responder 51 squamous histology 51 docetaxel Taxotere ® 51 EGFR tyrosine kinase inhibitors 51 TTR gene 51 tigecycline 51 Phase 2a trial 51 subsyndromal 51 Tamibarotene 51 neoadjuvant 51 temsirolimus 51 cell acute lymphoblastic 51 lymphocytic leukemia 51 PEGylated anti 51 non selective NSAIDs 51 acute lymphoblastic 51 alemtuzumab treated 51 gemcitabine 51 cells PBMCs 51 pharmacodynamic endpoints 51 Leukemias 51 DMARD therapy 51 anemias 51 IAP inhibitor 51 epratuzumab 51 liposomal doxorubicin 51 sclerosing 51 ischemic cardiomyopathy 51 GAMMAGARD 51 overlapping toxicities 51 levodopa therapy 51 myelosuppressive 51 IIIB NSCLC 51 gastrointestinal stromal tumors GISTs 51 ENMD # 51 pituitary adenomas 51 EGFR expressing mCRC 51 oral diclofenac 51 endoscopic remission 51 purpura ITP 51 Synovial sarcoma 51 gastrointestinal stromal tumor GIST 51 dose escalation phase 51 Acute myeloid leukemia AML 51 JAK1 51 biochemical abnormalities 51 Vectibix monotherapy 51 coagulopathy 51 Hodgkin lymphomas 51 coagulation disorders 51 imatinib mesylate 51 demyelinating disease 51 recurrent malignant glioma 51 proliferative diabetic retinopathy 51 acute leukemias 51 polycythemia vera essential thrombocythemia 51 palliation 51 etanercept 51 pericardial effusion 51 dysmotility 51 YONDELIS 51 cervical lymph nodes 51 liver metastases 51 thrombocytopenic 51 octreotide 51 EFAPROXYN 51 vinca alkaloid 51 axitinib 51 JAK inhibitors 51 immune modulating 51 surgical debulking 51 preclinical xenograft models 51 pharmacokinetic PK 51 undetectable HBV DNA 51 alefacept 51 bortezomib refractory 51 orally administered inhibitor 51 Myelodysplastic Syndrome MDS 51 sunitinib 51 deferiprone 51 complement inhibitor eculizumab 51 fungoides 51 Virulizin ® 51 gastrointestinal stromal tumors 51 Xcytrin 51 colorectal carcinoma 51 hyperphenylalaninemia HPA due 51 serum phosphate 51 OvaRex MAb 51 dasatinib Sprycel 51 alanine transaminase ALT 51 docetaxel Taxotere 51 hamartomas 51 sunitinib Sutent 51 invasive candidiasis 51 lymphoid cells 51 malignant neoplasm 51 VELCADE melphalan 51 tolerability profiles 51 pan HDAC inhibitor 51 endometrioid 51 achieved CCyR 51 metastatic uveal melanoma 51 DMARDs 51 neoadjuvant radiation 51 lymphadenopathy 51 clevidipine 51 ipsilateral breast 51 metastatic renal cell 51 aflibercept VEGF Trap 51 recurrent glioma 51 PC# cells 51 demyelinating diseases 51 IMGN# 51 taxane refractory 51 JAK2 inhibitors 51 CanAg 51 tyrosine kinase inhibitor 51 bortezomib Velcade 51 caspofungin 51 biochemical relapse 51 tocilizumab 51 busulfan 51 clofarabine 51 dose cytarabine 51 granulomatous 51 Pemetrexed 51 Peg IFN 51 graft dysfunction 51 peripheral neuropathy 51 S/GSK# 51 QTc prolongation 51 sunitinib Sutent ® 51 HIV HCV coinfected 51 interferon IFN 51 chronic myelogenous leukemia CML 51 SCIg 51 FOLOTYN 51 receptor inhibitor 51 parathyroidectomy 51 elevated creatinine 51 pemphigus vulgaris 51 receiving golimumab 51 enzastaurin 51 antitumor efficacy 51 efficacy endpoint 51 vidofludimus 51 HeFH 51 seminomas 51 amrubicin 51 Scale EDSS 50 romidepsin 50 homozygous familial hypercholesterolemia 50 p# inhibitor 50 virologic response 50 humanized anti 50 antitumor effects 50 cyclophosphamide 50 nucleoside analogs 50 cetuximab Erbitux R 50 Genasense ® 50 neoadjuvant chemotherapy 50 extracranial 50 sorafenib Nexavar 50 durable remissions 50 Pixantrone 50 % CI #.#-#.# [007] 50 Erythropoietic therapies may 50 CML CP 50 cardiac troponin 50 EDEMA3 trial 50 Traficet EN 50 subependymal giant cell 50 glial tumors 50 imipenem 50 Panzem R NCD 50 hepatocellular carcinoma 50 baminercept 50 obatoclax 50 serum urate 50 Cloretazine R VNP#M 50 fosbretabulin 50 Brentuximab Vedotin SGN 50 neovascular 50 hemolytic anemia 50 lymph node enlargement 50 polyarticular 50 interferon ribavirin 50 esophageal candidiasis 50 Chronic lymphocytic leukemia 50 Chronic myeloid leukemia 50 immunohistochemical staining 50 cetuximab Erbitux ® 50 transplantation HCT 50 progressive PsA 50 etiologies 50 iobenguane 50 Velcade bortezomib 50 mucosal healing 50 vitro cytotoxicity 50 PRTX 50 IVIg 50 seliciclib 50 mg m² 50 Cimzia TM 50 Li Fraumeni Syndrome 50 pegfilgrastim 50 trans retinoic acid ATRA 50 MEK inhibitors 50 basal cell carcinomas 50 androgen ablation 50 calcineurin inhibitor 50 relapsing multiple sclerosis 50 pegylated interferon alpha 50 platelet reactivity 50 Ganetespib 50 pancreatic ovarian 50 anakinra 50 lymphoma leukemia 50 HuMax CD4 50 EGFR mutation positive 50 spinal cord compression 50 myoclonus 50 MGCD# [001] 50 Relapsing remitting MS 50 irinotecan containing 50 lamivudine refractory patients 50 cytotoxicity 50 mitoxantrone chemotherapy 50 ispinesib administered 50 HAAH 50 FOLFIRI alone 50 metastatic sarcoma 50 VELCADE 50 PRT# 50 pulmonary metastases 50 histologic subtypes 50 non splenectomized 50 methotrexate therapy 50 GMX# 50 BEXXAR Therapeutic Regimen 50 Crohn Disease Activity 50 relapsed refractory ALL 50 histone deacetylase HDAC inhibitor 50 allogeneic transplantation 50 Anaplastic 50 dacetuzumab 50 GRN#L 50 taxane chemotherapy 50 alvespimycin 50 secondary endpoints 50 Secondary endpoints included 50 Marqibo 50 BARACLUDE ® 50 autoimmune hemolytic anemia 50 OXi# 50 Imprime PGG 50 HNSCC 50 5-FU/LV 50 cisplatin resistant 50 thymic carcinoma 50 docetaxel 50 immunomodulatory agents 50 adjuvant systemic

Back to home page